Literature DB >> 17639375

Radiofrequency ablation of problematically located hepatocellular carcinoma: tailored approach.

Min-Hua Chen1, Wei Yang, Kun Yan, Yi-Bin Hou, Ying Dai, Wen Gao, Hui Zhang, Wei Wu.   

Abstract

BACKGROUND: The challenge for radiofrequency ablation (RFA) of hepatocellular carcinomas (HCC) in problematic locations is that the outcome is limited due to insufficient ablation or injury of nearby structures. This study aimed to evaluate effective strategy and treatment results of RFA in these cases.
METHODS: Ultrasound guided percutaneous RFA was performed in 326 HCC patients. Among them, 249 tumors in 215 patients located at liver periphery, including 54 adjacent to GI tract, 110 close to the diaphragm, 49 close to the gallbladder, and 36 tumors close to liver surface. The sizes of the tumors ranged 1.2-7.0 cm (average 3.7 +/- 1.3 cm). Individualized treatment strategy was established for tumors in various locations, including "artificial ascites", "lift-expand" electrode placement, "draw-expand" electrode placement, "Supplementary ablation", and "accumulative multiple ablations" techniques. Treatment outcome was compared with another 64 central-located tumors (control group) in the same patients. One-month post-RFA contrast CT was used to evaluate early necrosis rate of the treated tumors.
RESULTS: Early tumor necrosis were obtained in 91.6% (228/249) of the problematically located HCC, including 90.7% (49/54) of the tumors adjacent to GI tract, 90.9% (100/110) near the diaphragm, 91.8% (45/49) by the gallbladder, and 94.4% (34/36) close to liver surface. The necrosis rate of control group was 98.4% (63/64), which was higher than the tumors close to diaphragm (P = 0.049). Local tumor recurrence was 8.4% (21/249), comparing with 3.1% (2/64) of the control group (P > 0.05). The 1-, 2- and 3-year survival rate of this group were 81.6%, 63.8%, and 53.6%, respectively. Major complications occurred in 3.2% (11/343) of the treatment sessions, including hemorrhage in two, nearby structure injury in five, and needle tract seeding in four patients.
CONCLUSIONS: Individualized treatment strategy for problematically located HCC is helpful in improving RFA outcome and expanding the application range of the therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17639375     DOI: 10.1007/s00261-007-9283-4

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  20 in total

1.  Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes.

Authors:  Wei Yang; Kun Yan; Gong-Xiong Wu; Wei Wu; Ying Fu; Jung-Chieh Lee; Zhong-Yi Zhang; Song Wang; Min-Hua Chen
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations.

Authors:  Bo-Shuai Yang; Ling-Xiao Liu; Min Yuan; Yi-Bin Hou; Qing-Tao Li; Su Zhou; Yu-Xin Shi; Bu-Lang Gao
Journal:  Diagn Interv Radiol       Date:  2020-03       Impact factor: 2.630

3.  Percutaneous radiofrequency ablation versus partial hepatectomy for small centrally located hepatocellular carcinoma.

Authors:  Wei-Xing Guo; Ju-Xian Sun; Yu-Qiang Cheng; Jie Shi; Nan Li; Jie Xue; Meng-Chao Wu; Yi Chen; Shu-Qun Cheng
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

4.  Reducing Pain by Artificial Ascites Infusion During Radiofrequency Ablation for Subcapsular Hepatocellular Carcinoma.

Authors:  Sae-Jin Park; Dong Ho Lee; Joon Koo Han
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-03       Impact factor: 2.740

Review 5.  Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma.

Authors:  Chia-Chi Wang; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-06-25       Impact factor: 6.047

6.  Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results.

Authors:  John Wong; Kit-Fai Lee; Simon Chun-Ho Yu; Paul Sing-Fun Lee; Yue-Sun Cheung; Ching-Ning Chong; Philip Ching-Tak Ip; Paul Bo-San Lai
Journal:  HPB (Oxford)       Date:  2012-11-28       Impact factor: 3.647

7.  Percutaneous radiofrequency ablation of hepatocellular carcinomas adjacent to the gallbladder with internally cooled electrodes: assessment of safety and therapeutic efficacy.

Authors:  Sang Won Kim; Hyunchul Rhim; Mihyun Park; Heejung Kim; Young-sun Kim; Dongil Choi; Hyo K Lim
Journal:  Korean J Radiol       Date:  2009-06-25       Impact factor: 3.500

8.  Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment.

Authors:  Wei Yang; Kun Yan; S Nahum Goldberg; Muneeb Ahmed; Jung-Chieh Lee; Wei Wu; Zhong-Yi Zhang; Song Wang; Min-Hua Chen
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

9.  Radiofrequency ablation for postoperative recurrences of intrahepatic cholangiocarcinoma.

Authors:  Ying Fu; Wei Yang; Wei Wu; Kun Yan; Bao-Cai Xing; Min-Hua Chen
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

10.  Role of contrast enhanced ultrasound in radiofrequency ablation of metastatic liver carcinoma.

Authors:  Jin-Yu Wu; Min-Hua Chen; Wei Yang; Shu-Zhi Lin; Wei Wu; Shan-Shan Yin; Hui Zhang; Kun Yan
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.